以岭药业：全资子公司撤回“柴黄利胆胶囊”药品注册申请

Core Viewpoint - Yiling Pharmaceutical announced that its wholly-owned subsidiary, Beijing Yiling, received notification from the National Medical Products Administration to withdraw the drug registration application for "Chai Huang Li Dan Capsule" [1] Group 1: Drug Registration - The drug is an innovative traditional Chinese medicine developed by the company [1] - The new drug registration application was accepted in 2024 [1] - Beijing Yiling will improve the registration materials and resubmit the application as soon as possible [1] Group 2: Impact on Business - The withdrawal is expected not to have a significant impact on the company's current and future production operations and performance [1] - The company will monitor subsequent developments and disclose updates in a timely manner [1]